Delfi Limited P34

NEW YORK, July 30, 2026--Delfi joins Circuit Accelerator to bring agentic AI balance sheet decisioning and capital markets tools to credit unions and their finance teams.

SLB agrees to acquire Tachyus to add AI-powered reservoir optimization tools, expanding its digital portfolio and strengthening recovery-focused solutions.

DELFI Diagnostics, Inc., developer of AI-powered, blood-based tests for cancer detection, today announced it has received a Clinical Laboratory Permit and Test Approval letter from the New York State Department of Health (NYSDOH). With this permit, DELFI is now authorized to offer its FirstLook™ Lung laboratory-developed test (LDT) in New York. The test is now available in all 50 U.S. states.

DELFI Diagnostics, Inc., developer of innovative AI-powered blood-based tests that leverage cell-free DNA (cfDNA) fragmentomics for cancer detection and monitoring, today announced the appointment of Charles "Charlie" Newton to its Board of Directors. Mr. Newton brings nearly three decades of healthcare finance and executive leadership experience to DELFI as the company reads out pivotal data that advances its lead product, FirstLook™ Lung, toward FDA submission and positions it for broad commer

Delfi Limited's ( SGX:P34 ) stock was strong despite it releasing a soft earnings report last week. However, we think...

The total number of digital subscriptions of AS Ekspress Grupp increased by 6% in the Baltic States year-over-year (1st quarter: -3%) and totalled 237 136 at the end of March. The number of digital subscriptions of AS Delfi Meedia that publishes the news portal Delfi, newspapers Maaleht, Eesti Ekspress and several popular magazines increased by 8% year-over-year (1st quarter: -3%) and totalled 121 407.The number of digital subscriptions of AS Õhtuleht Kirjastus, 50% of which is owned by Ekspress